Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Generation Bio Co. GBIO
$4.44
-$0.14 (-3.06%)
На 18:02, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
311244225.00000000
-
week52high
8.72
-
week52low
3.40
-
Revenue
0
-
P/E TTM
-2
-
Beta
1.95858400
-
EPS
-2.30000000
-
Last Dividend
0.00000000
-
Next Earnings Date
02 авг 2023 г. в 10:59
Описание компании
Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| JMP Securities | Market Outperform | Market Outperform | 08 авг 2022 г. |
| Needham | Buy | Buy | 05 авг 2022 г. |
| Needham | Buy | Buy | 15 дек 2021 г. |
| JMP Securities | Market Outperform | Market Outperform | 15 дек 2021 г. |
| JMP Securities | Market Outperform | 08 июн 2021 г. | |
| Canaccord Genuity | Buy | 08 ноя 2022 г. | |
| JMP Securities | Market Outperform | Market Outperform | 19 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Paone Antoinette | D | 0 | 2695 | 26 янв 2023 г. |
| Kerr Douglas | A | 26775 | 26775 | 20 янв 2023 г. |
| Kerr Douglas | A | 53550 | 53550 | 20 янв 2023 г. |
| Paone Antoinette | A | 25467 | 25467 | 20 янв 2023 г. |
| Paone Antoinette | A | 50935 | 50935 | 20 янв 2023 г. |
| MCDONOUGH GEOFF | A | 84375 | 84375 | 20 янв 2023 г. |
| MCDONOUGH GEOFF | A | 168750 | 168750 | 20 янв 2023 г. |
| Stanton Matthew | A | 26775 | 26775 | 20 янв 2023 г. |
| Stanton Matthew | A | 53550 | 53550 | 20 янв 2023 г. |
| Zimmermann Tracy | A | 26775 | 26775 | 20 янв 2023 г. |
Новостная лента
Generation Bio to Present at the 41st Annual J.P. Morgan Healthcare Conference
GlobeNewsWire
03 янв 2023 г. в 16:30
CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that the company will present at the 41st Annual J.P. Morgan Healthcare Conference on January 10th at 4:30 p.m. PST in San Francisco, CA.
Generation Bio to Present at the 2022 Jefferies Cell and Genetic Medicine Summit
GlobeNewsWire
22 сент 2022 г. в 07:30
CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that the company will participate in a fireside chat at the 2022 Jefferies Cell & Genetic Medicine Summit on Thursday, September 29th at 10:30 a.m. ET in New York.
Generation Bio Co. (GBIO) Reports Q2 Loss, Misses Revenue Estimates
Zacks Investment Research
04 авг 2022 г. в 18:48
Generation Bio Co. (GBIO) delivered earnings and revenue surprises of -4.76% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Generation Bio to Present at the 2022 Wedbush PacGrow Healthcare Conference
GlobeNewsWire
02 авг 2022 г. в 16:15
CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that the company will participate in a panel at the virtual 2022 Wedbush PacGrow Healthcare Conference on Tuesday, August 9th at 9:45 a.m. ET.
Wall Street Analysts See a 174% Upside in Generation Bio Co. (GBIO): Can the Stock Really Move This High?
Zacks Investment Research
11 июл 2022 г. в 11:36
The average of price targets set by Wall Street analysts indicates a potential upside of 173.7% in Generation Bio Co. (GBIO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.